New Zealand markets open in 8 hours 51 minutes

Seagen Inc. (SGEN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
170.14-3.90 (-2.24%)
At close: 04:00PM EDT
172.00 +1.86 (+1.09%)
Pre-market: 09:08AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close174.04
Bid168.00 x 1100
Ask173.00 x 1200
Day's range164.82 - 175.70
52-week range105.43 - 192.79
Avg. volume1,363,493
Market cap31.38B
Beta (5Y monthly)0.57
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Seagen Statement on Outcome of Daiichi Sankyo Arbitration

    BOTHELL, Wash., August 12, 2022--Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. ("Daiichi Sankyo") relating to the parties’ 2008 collaboration agreement for the use of Seagen’s antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen on the interpretation of the contract.

  • Business Wire

    Seagen Reports Second Quarter 2022 Financial Results

    BOTHELL, Wash., July 28, 2022--Seagen Inc. (Nasdaq:SGEN) reported financial results today for the second quarter ended June 30, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its deep and diverse oncology pipeline.

  • Business Wire

    Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

    BOTHELL, Wash. & TOKYO, July 26, 2022--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K evaluating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer (la/m